Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies

AIDS

Volumn 11, Issue 8, 1997, Pages 969-975

  Bongertz, Vera ^a,d   Costa, Catia I ^a   Santos, Valdiléa G V ^b   João Filho, Esaú C ^c   Galvão Castro, Bernardo ^d   Morgado, Mariza G ^a  

^a Department Immunology   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c State Employee Hospital   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Autologous neutralization; Heterologous neutralization; Primary HIV 1 isolates

Indexed keywords

ANTIGEN P24; AUTOANTIBODY; NEUTRALIZING ANTIBODY;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; BISEXUALITY; BRAZIL; FEMALE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; MALE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANIMALS; FEMALE; GOATS; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV SEROPOSITIVITY; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS;

EID: 0031010244     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199708000-00004     Document Type: Article

References (25)

1. Ho DD, Rota TR, Hirsch MS: Antibody to lymphoadenopathy-associated virus [letter]. N Engl J Med 1985, 312:649-650.
2. Robert-Guroff M, Brown M, Gallo RC: HTLV-III neutralising antibodies in patients with AIDS and AIDS-related complex. Nature 1985, 316:72-74.
3. Weiss RA, Clapham PR, Cheingsong-Popov R, et al.: Neutralisation of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985, 316:69-72.
4. Matthews TJ: The dilemma of neutralization resistance of HIV-1 field isolates and vaccine development [letter]. AIDS Res Hum Retroviruses 1994, 10:631-632.
5. Moore JP, Cao Y, Qing L, et al.: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 1995, 69:101-109.
6. Bou-Habib DC, Roderoquez G, Oravecz T, Berman PW, Lusso P, Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994, 68:6006-6013.
7. Gorny MK, Moore JP, Conley AJ, et al.: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994, 68:8312-8320.
8. Sawyer LW, Wrin MT, Crawford-Miksza L, et al.: Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol 1994, 68:1342-1349.
9. Scarlatti G, Albert J, Rossi P, et al.: Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993, 168:207-210.
10. Tremblay M, Wainberg MA: Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis 1990, 162:735-737.
11. Vittecoq D, Chevret S, Morand-Joubert L, et al.: Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995, 92:1195-1199.
12. Carrow EW, Vujcic LK, Glass WL, et al.: High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1 MN in sera from Africa and the Americas. AIDS Res Hum Retroviruses 1991, 7:831-838.
13. Bongertz V, Morgado MG, Galvão-Castro B, Wigzell H, Hendry RM: Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals residing in Brazil. Mem Inst Oswaldo Cruz 1994, 89:113-114.
14. Centers for Disease Control: Classification system for human T-lymphotropic virus type III/lymphoadenopathy associated virus infections. Ann Intern Med 1986, 105:234-237.
15. Ruebsamen-Waigmann H, Von Briesen H, Holmes H, et al.: Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world. AIDS Res Hum Retroviruses 1994, 10:1401-1408.
16. Albert J, Abrahamson B, Nagy K, et al.: Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990, 4:107-112.
17. Albert J, Bjoerling E, Von Gegerfelt A, et al.: Antigen detection is a reliable method for evaluating HIV/SIV neutralization assays. AIDS Res Hum Retroviruses 1993, 9:501-504.
18. Delwart EL, Shpaer EG, Louwagie J, et al.: Genetic relationships determined by a DNA heteroduplex motility assay: analysis of HIV-1 env genes. Science 1993, 262:1257-1261.
19. Arendrup M, Soennerborg A, Svennerholm B, et al.: Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol 1993, 74:855-863.
20. Montefiori DC, Zhou J, Barnes B, Lake D, Hersh EM, Masuho Y, Lefkowitz JB Jr: Homotypic antibody response to fresh clinical isolates of human immunodeficiency virus. Virology 1991, 182:635-643.
21. Bjoerling E, Scarlatti G, Von Gegerfelt A, et al.: Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993, 193:528-530.
22. Arendrup M, Nielsen C, Hansen JES, Pedersen C, Mathiesen L, Nielsen JO: Autologous HIV-1 neutralizing antibodies: emergence of neutralization resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr 1992, 5:303-307.
23. Watkins BA, Reitz MS, Wilson CA, Aldrich A, Davis AE, Robert-Guroff M: Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies. J Virol 1993, 67:7493-7500.
24. Galvão-Castro B, Couto Fernandez JC, Mello MA, et al.: A nationwide effort to systematically monitor HIV-1 diversity in Brazil. Mem Inst Oswaldo Cruz 1996, 91:335-338.
25. Rencher SD, Slobod KS, Dawson DS, Lockey TD, Hurwitz L: Does the key to a successful HIV type 1 vaccine lie among the envelope sequences of infected individuals? AIDS Res Hum Retroviruses 1995, 11:1131-1133.